Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until June, 2020.

  1. Oligonucleotide Enzyme Surrogate (OnES)

    SBC: Accacia International LLC            Topic: CBD08108

    Historically organophosphorus compounds such as insecticides and nerve agents have been susceptible to decomposition by proteinaceous enzymes. Organophosphate hydrolases (OPH) represent a practical method to deactivate such compounds peripherally and on surfaces. However, when such organophosphates are ingested, the use of proteinaceous enzymes such as OPH can be problematic because of their tende ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  2. Carbon Nanotube-Based Filters for Aerosol Sample Collection

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD07111

    Aerosols represent one of the more efficient methods to distribute biological and chemical agents throughout the atmosphere. Small aerosol droplets can be readily inhaled and easily penetrate deep into the lungs where they lodge in bronchial alveoli. Within the alveoli, chemical and biological agents can breach epithelial and endothelial cell layers and enter the bloodstream, where they cause da ...

    SBIR Phase I 2007 Department of DefenseOffice for Chemical and Biological Defense
  3. Ribozymes for In Vivo Degradation of G-Nerve Agents

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD08108

    Given the possibility to administer prophylactic doses of protein bioscavengers inactivating OP nerve agents before they reach their acetylcholinesterase target, much attention has been given to proteins such as human butyrylcholinesterase and paraoxonase I. As small nucleic acid catalysts can exhibit triphosphoesterase activities, the identification of new molecules active against nerve agents w ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  4. Collective Protection for Military Working Dogs

    SBC: AGAVE BIOSYSTEMS INC.            Topic: CBD08103

    Shelter enclosures for military working dogs in the event of a CB attack is a technology gap identified by the Joint Requirements Office. Important parameters to consider in the design of protective enclosures include low weight and size to minimize transport requirements; rapid setup; and accommodation of canine physiological and psychological comfort needs. The overall operational weight of th ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  5. Multiple Indication Adjuvants

    SBC: BIOPROTECTION SYSTEMS CORP.            Topic: CBD08105

    The objective of this study is to demonstrate the efficacy and broad applicability of the human immune-modulating alphaGal Adjuvant Technology for antiviral vaccine development. We will use viral vaccine candidates for the select Category A viral pathogens Zaire ebolavirus (ZEBOV, filovirus), Rift Valley fever virus (RVFV, bunyavirus), and Lassa virus (LV, arenavirus), to evaluate the adjuvant pot ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
  6. Development of a Database Management System to Enable Rapid, Efficient Assay Design for Use in Detection and Diagnosis of Human Exposure to Biological

    SBC: CFD Research Corporation            Topic: CBD07114

    The primary objective of this effort is to design and develop a database management system (DBMS) and enable the integrated interpretation of the vast amounts of genomic and proteomic data in proper biological context. This DBMS will enable the development of diagnostic assays for human exposure to specific biological threat agents using an existing suite of systems biology tools. The DBMS design ...

    SBIR Phase I 2007 Department of DefenseOffice for Chemical and Biological Defense
  7. Development of a Database Management System to Enable Rapid, Efficient Assay Design for Use in Detection and Diagnosis of Human Exposure to Biological

    SBC: CFD Research Corporation            Topic: CBD07114

    Increases in amount and diversity of high-throughput data presents tremendous organizational and analysis challenges to researchers. Our objective in this effort is to address these challenges by designing and implementing a database management system (cipherDB) for the storage, management, analysis, and visualization of diverse biological data types. The Phase I design and implementation of ciphe ...

    SBIR Phase II 2008 Department of DefenseOffice for Chemical and Biological Defense
  8. Generic Adsorptive Carbon Residual Life Indicator

    SBC: MORPHIX TECHNOLOGIES, INC.            Topic: CBD07103

    Carbon based filtration technologies have several known modes of degradation and failure including adsorption of chemical contaminants, adsorption of environmental pollutants and operational interferents, repeated moisture condensation, and moisture vapor adsorption. In unknown hazardous environments, the ultimate End-of-Service-Life Indicator (ESLI)/Residual Life Indicator (RLI) for critical Ind ...

    SBIR Phase I 2007 Department of DefenseOffice for Chemical and Biological Defense
  9. Generic Adsorptive Carbon Residual Life Indicator

    SBC: MORPHIX TECHNOLOGIES, INC.            Topic: CBD07103

    Generic residual life indicator technology developed under PI effort will be matured through reduction of COTS items used in the breadboard design to a miniaturized brassboard system capable of detecting agent saturation front migration through a sorbent. The capability of this brassboard system to detect representative agents from several classes will be demonstrated along with the ability to pr ...

    SBIR Phase II 2008 Department of DefenseOffice for Chemical and Biological Defense
  10. Blood Brain Barrier (BBB) Permeable Encapsulating Agents for Effective Delivery of CNS-active Agents

    SBC: Lynntech Inc.            Topic: CBD08107

    Drug transport in the central nervous system is highly regulated by the Blood-Brain Barrier (BBB). Most medicines, including many for treating cancer, Alzheimer’s, and stroke, do not meet essential criteria, such as lipophilicity and low molecular weight, required for appreciable transport into the brain. However, endogenous peptides, such as insulin or transferrin, and certain monoclonal anti ...

    SBIR Phase I 2008 Department of DefenseOffice for Chemical and Biological Defense
US Flag An Official Website of the United States Government